MENLO PARK, Calif., Aug. 13 /PRNewswire-FirstCall/ -- XTENT, Inc. announced today that Michael L. Eagle, former Vice President, Manufacturing, at Eli Lilly and Company, has been appointed to the company’s Board of Directors.
“We are very fortunate to have Mike Eagle join our Board of Directors as we ramp up production in preparation for our pivotal studies and future commercialization of our Custom NX(R) drug eluting stent systems,” said Gregory D. Casciaro, XTENT’s President and CEO. “We will benefit greatly from his experience in the life sciences industry and he will complement the vast skill set we already have on the Board.”
Mr. Eagle has over 30 years of experience in manufacturing and general management. Prior to serving at Eli Lilly and Company for eight years as Vice President of Manufacturing, Mr. Eagle was Chief Executive Officer of IVAC Corporation, and served as the Senior Vice President of Operations of the Medical Devices and Diagnostics Division of Eli Lilly, which became Guidant Corporation after its 1995 spinoff from Eli Lilly. Mr. Eagle is Chairman of the Board of Directors of Favrille, Inc., and a member of the boards of Radiant Medical, Siegel-Robert Corporation, Somaxon Pharmaceutical, and Micrus Endovascular. Mr. Eagle received his Bachelor of Science Degree in Mechanical Engineering from Kettering University and his Masters Degree in Business Administration from the Krannert School of Management at Purdue University.
About XTENT
XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning the timing of XTENT’s U.S. pivotal trial, commercialization of its products or the achievement of any other clinical, regulatory or product development milestones. Forward-looking statements are based on management’s current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the “Risk Factors” section of our most recent quarterly report on Form 10-Q for the quarter ended June 30, 2007. The quarterly report was filed with the SEC on August 13, 2007, and is available on our investor relations website at http://www.xtentinc.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. XTENT undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
XTENT, Inc.
CONTACT: investors, Tim Kahlenberg, Chief Financial Officer of XTENT,Inc., +1-650-475-9400, tkahlenberg@xtentinc.com; or media, Aimee Corso,+1-310-780-2661, acorso@weisscommpartners.com, or Julio Cantre,+1-415-946-1055, jcantre@weisscommpartners.com, both for XTENT, Inc.
Web site: http://www.xtentinc.com//
